Chitosan-based injectable porous microcarriers with enhanced adipogenic differentiation and angiogenesis for subcutaneous adipose tissue regeneration.
Gan Y., Han H., Zhang Y., Zhou Z., Shen X., Fang J.
Animal Study, published in Biomater Adv (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomater Adv (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39756088
- DOI
- 10.1016/j.bioadv.2025.214174
- Citations
- 2
Abstract (original English)
Chitosan is a promising biomaterial for tissue engineering, but its functionality is limited by a lack of bioactive sites. This study develops chitosan/amniotic membrane microcarriers to enhance vascularization and tissue regeneration for subcutaneous adipose tissue. The incorporation of decellularized amniotic membrane enhances the bioactivities of chitosan in promoting cell differentiation and angiogenesis. Optimized preparation yielded porous microcarriers with a particle size of 261.2 ± 28 μm and an average pore size of 19.0 ± 4 μm. In vitro degradation analysis showed accelerated degradation with higher amniotic membrane content. Cytocompatibility and adipogenic capacity assessments indicated that the microcarriers supported cell adhesion and proliferation over 7 days, with amniotic membrane facilitating adipogenic differentiation of adipose-derived stem cells. When injected subcutaneously into nude mice, these microcarriers formed neoplastic adipose tissues, which were harvested 8 weeks later. Fluorescence staining, oil-red O staining and CD31 labeling demonstrated that amniotic membrane incorporation significantly enhanced in vivo adipose tissue formation and angiogenesis.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.